Bio-Path (NASDAQ:BPTH) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH) in a research note released on Tuesday morning. The firm issued a sell rating on the stock.

Bio-Path Price Performance

NASDAQ BPTH opened at $0.18 on Tuesday. Bio-Path has a 1-year low of $0.12 and a 1-year high of $4.55. The stock has a 50-day moving average of $0.16 and a 200-day moving average of $0.56.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.